Disease
ORAL
COMPOUND
COMPOUND
Discovery
Preclinical
Phase 1
Phase 2
Neuromuscular:Sarcopenia
MF-300
MF-300 is a “first-in-class” sarcopenia therapy. Sarcopenia is a large unmet need with no FDA approved therapies.
Spinal Muscular Atrophy
Not Disclosed
Fibrotic:Idiopathic Pulmonary Fibrosis
Not Disclosed
Pipeline Expansion
Neuromuscular
Bone
Fibrosis
Neuroinflammation
Bone
Fibrosis
Neuroinflammation